Pharmacokinetic and pharmacodynamic factors that can affect sensitivity to neurotoxic sequelae in elderly individuals

Environmental Health Perspectives

Volumn 113, Issue 9, 2005, Pages 1243-1249

  Ginsberg, Gary ^a   Hattis, Dale ^b   Russ, Abel ^b   Sonawane, Babasaheb ^c  

^a CDC   (United States)

^b CLARK UNIVERSITY   (United States)

^c U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Adverse drug reactions; Geriatric; Metabolism; Neurotoxicity; Pharmacokinetics; Polypharmacy

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ACICLOVIR; ALCOHOL; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOTRANSFERASE; AMPHOTERICIN B; BENZODIAZEPINE DERIVATIVE; CARBAMATE INSECTICIDE; CARCINOGEN; CHEMICAL WARFARE AGENT; CISPLATIN; CYTOCHROME P450; DIAZEPAM; DIOXIN; ENVIRONMENTAL CHEMICAL; FLUOXETINE; ISONIAZID; LORAZEPAM; MANEB; NONSTEROID ANTIINFLAMMATORY AGENT; ORGANOPHOSPHATE INSECTICIDE; PARAQUAT; PARATHION; PAROXETINE; PEROXISOME PROLIFERATOR; PHENOBARBITAL; RIFAMPICIN; SEROTONIN UPTAKE INHIBITOR; UNINDEXED DRUG; XENOBIOTIC AGENT;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; AGING; AMINOTRANSFERASE BLOOD LEVEL; ANXIETY DISORDER; AREA UNDER THE CURVE; DATA BASE; DEPRESSION; DISEASE PREDISPOSITION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG PREFERENCE; DRUG RETENTION; ELDERLY CARE; GENOTOXICITY; HIGH RISK POPULATION; HUMAN; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY FAILURE; LIVER CANCER; LIVER DISEASE; LIVER TOXICITY; LUNG TUBERCULOSIS; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; PHARMACODYNAMICS; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; TOXICOKINETICS; XENOBIOTIC METABOLISM;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL POLLUTANTS; HUMANS; KIDNEY DISEASES; LIVER DISEASES; NERVOUS SYSTEM DISEASES; PHARMACEUTICAL PREPARATIONS; POLYPHARMACY; XENOBIOTICS;

EID: 25844458497     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.7568     Document Type: Review

References (69)

1. Adler M, Goubau P, Nevens F, Van Vlierberghe H. 2002. Hepatitis C virus: the burden of the disease. Acta Gastroenterol Belg 65:83-86.
2. Ali SF, David SN, Newport GD. 1993. Age related susceptibility to MPTP-induced neurotoxicity in mice. Neurotoxicology 14:29-34.
3. Amarapurkar D, Das HS. 2002. Chronic liver disease in diabetes mellitus. Trop Gastroenterol 23:3-5.
4. Anantharaju A, Feller A, Chedid A. 2002. Aging liver. Gerontology 48:343-353.
5. Barclay AM. 1985. Psychotropic drugs in the elderly. Selection of the appropriate agent. Postgrad Med 77:153-157, 160-162.
6. Barone S, Stanton ME, Mundy WR. 2001. Latent effects of developmental exposure to neurotoxicants indicate compensation may come at cost later in life [Abstract]. Teratology 63:6A-7A.
7. Bartus RT, Dean RL, Beer B, Lippa AS. 1982. The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408-417.
8. Begaud B, Martin K, Fourrier A, Haramburu F. 2002. Does age increase the risk of adverse drug reactions? Br J Clin Pharmacol 54:548-552.
9. Bourin M, Chue P, Guillon Y. 2001. Paroxetine: a review. CNS Drug Rev 7:25-47.
10. Bowyer JF, Frame LT, Clausing P, Nagamot-Combs K, Osterhout CA, Sterling CR, et al. 1998. Long-term effects of amphetamine neurotoxicity on tyrosine hydroxylase mRNA and protein in aged rats. J Pharmacol Exp Therap 286:1074-1085.
11. Carbonin P, Pahor M, Bernabei R, Sgadari A. 1991. Is age an independent risk factor of adverse drug reactions in hospitalized medical patients? Am Geriatr Soc 39:1093-1099.
12. Cattley RC, Marsman DS, Popp JA. 1991. Age-related susceptibility to the carcinogenic effect of the peroxisome proliferator WY-14,643 in rat liver. Carcinogenesis 12:469-473.
13. Clewell HJ, Teeguarden J, McDonald T, Sarangapani R, Lawrence G, Covington T, et al. 2002. Review and evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Crit Rev Toxicol 32:329-389.
14. Craft NE, Haitema TB, Garnett KM, Fitch KA, Dorey CK. 2004. Carotenoid, tocopherol, and retinol concentrations in elderly human brain. J Nutr Health Aging 8:156-162.
15. Cutler NR, Narang PK. 1984. Implications of dosing tricyclic anti-depressants and benzodiazepines in geriatrics. Psychiatr Clin North Am 7:845-861.
16. Dollery CT. 1999. Therapeutic Drugs. 2nd ed. New York:Churchill Livingstone.
17. Ginsberg G, Hattis D, Sonawane B, Russ A, Banati P, Kozlak M, et al. 2002. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci 66:185-200.
18. Girgis L, Brooks P. 1994. Nonsteroidal anti-inflammatory drugs: differential use in older patients. Drugs Aging 4:101-112.
19. Gomez CFJ, Luno J, Garcia de V, Valderrabano F. 1998. Renal vascular disease in the elderly. Kidney Int 68[suppl]:S73-S77.
20. Greenblatt DJ, Divoll M, Abernethy DR, Ochs HR, Shader RI. 1983. Benzodiazepine kinetics: implications for therapeutics and pharmacogeriatrics. Drug Metab Rev 14:251-292.
21. Hattis D, Russ A. 2003. Role of Dosimetric Scaling and Species Extrapolation in Evaluating Risks Across Life Stages. II. Pharmacokinetic Dosimetric Considerations in Old Age. Report to U.S. Environmental Protection Agency. RFQ no. DC-03-00009. Washington, DC:National Center for Environmental Assessment.
22. Hein HO, Suadicani P, Gyntelberg F. 1990. Mixed solvent exposure and cerebral symptoms among active and retired workers. An epidemiological investigation of 3387 men aged 53-75 years. Acta Neurol Scand 81:97-102.
23. Hemeryck A, Belpaire FM. 2002. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 3:13-37.
24. Hochberg F, Miller G, Valenzuela R, McNelis S, Crump KS, Covington T, et al. 1996. Late motor deficits of Chilean manganese miners: a blinded control study. Neurol 47:788-795.
25. Jansen PL. 2002. Liver disease in the elderly. Best Pract Res Clin Gastroenterol 16:149-158.
26. Johnson GL, Limon L, Trikha G, Wall H. 1994. Acute renal failure and neurotoxicity following oral acyclovir. Ann Pharmacother 28:460-463.
27. Karanth S, Pope C. 2000. Carboxylesterase and A-esterase activities during maturation and aging: relationship to the toxicity of chlorpyrifos and parathion in mice. Toxicol Sci 58:282-289.
28. Kraupp-Grasl B, Huber W, Taper H, Schulte-Hermann R. 1991. Increased susceptibility of aged rats to hepatocarcinogenesis by the peroxisome proliferator nafenopin and the possible involvement of altered liver foci occurring spontaneously. Cancer Res 51:666-671.
29. Lam YW, Banerji S, Hatfield C, Talbert RL. 1997. Principles of drug administration in renal insufficiency. Clin Pharmacokinet 32:30-57.
30. Larrey D. 2002. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Sem Liver Dis 22:145-155.
31. Lean MEJ, Han TS, Deurenberg P. 1996. Predicting body composition by densitometry from simple anthropometric measurements. Am J Clin Nutr 63:4-14.
32. LeCouteur DG, McLean AJ. 1998. The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 34:359-373.
33. Legha SS. 1990. Cisplatin neurotoxicity. N Engl J Med 323:365.
34. Liao, KH, Dobrev ID, Dennison JE, Andersen ME, Reisfeld B, Reardon KF, et al. 2002. Application of biologically based computer modeling to simple or complex mixtures. Environ Health Perspect 110(suppl 6):957-963.
35. Mahon MM, James OF. 1994. Liver disease in the elderly. J Clin Gastroenterol 18:330-334.
36. Masoro EJ, Snyder D. 2001. Exploration of Aging and Toxic Response Issues. Peer Review Report prepared for the U.S. Environmental Protection Agency. Contract 68-C-99-238. Washington, DC:National Center for Environmental Assessment.
37. McGeer PL, Itagaki S, Akiyama H, McGeer EG. 1988. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 24:574-576.
38. Michalek JE, Tripathi RC. 1999. Pharmacokinetics of TCDD in veterans of Operation Ranch Hand: 15-year follow-up. Toxicol Environ Health A 57:369-378.
39. Moser VC. 2001. Increased susceptibility of adults following developmental exposure to neurotoxicants: another susceptible population? Neurotoxicology 22:872.
40. Muhlberg W, Platt D. 1999. Age-dependent changes of the kidneys: pharmacological implications. Gerontology 45:243-253.
41. Mulder WJ, Hillen HF. 2001. Renal function and renal disease in the elderly: part I. Eur J Int Med 12:86-97.
42. Overstreet DH. 2000. Organophosphate pesticides, cholinergic function and cognitive performance in advanced age. Neurotoxicology 21:75-82.
43. Payton M, Riggs KM, Spiro A III, Weiss ST, Hu H. 1998. Relations of bone and blood lead to cognitive function: the VA Normative Aging Study. Neurotoxicol Teratol 20:19-27.
44. Pedigo NW. 1994. Neurotransmitter receptor plasticity in aging. Life Sci 55:1985-1991.
45. Pedigo NW, Minor LD, Krumrei TN. 1984. Cholinergic drug effects and brain muscarinic receptor binding in aged rats. Neurobiol Aging 5:227-233.
46. Perl TM, Bedard L, Kosatsky T, Hockin JC, Todd ECD, Remis RS. 1990. An outbreak of toxic encephalopathy caused by eating mussels contaminated with domoic acid. N Engl J Med 322:17755-1780.
47. Regev A, Schiff ER. 2001. Liver disease in the elderly. Gastroenterol Clin N Am 30:547-563.
48. Rifat SL, Eastwood MR, McLauchlan DR, Corey PN. 1990. Effect of exposure of miners to aluminum powder. Lancet 336(8724):1162-1165
49. Ritz E, Tarng DC. 2001. Renal disease in type 2 diabetes. Nephrol Dial Transplant 16(suppl 5):11-18.
50. Routledge PA, O'Mahony MS, Woodhouse KW. 2004. Adverse drug reactions in elderly patients. Br J Clin Pharmacol 57:121-126.
51. Schaberg T, Rebhan K, Lode H. 1996. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 9:2026-2030.
52. Schmucker DL. 2001. Liver function and phase I drug metabolism in the elderly. Drugs Aging 18:837-851.
53. Seymour RM, Routledge PA. 1998. Important drug-drug interactions in the elderly. Drugs Aging 12:485-494.
54. Sitte N, Merker K, Grune T, von Zglinicki T. 2000. Lipofuscin accumulation in proliferating fibroblasts in vitro: an indicator of oxidative stress. Exp Gerontol 36:475-486.
55. Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M. 1997. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 61:331-339.
56. Spina E, Scordo MG. 2002. Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 19:299-320.
57. Teitelbaum JS, Zatorre RJ, Carpenter S, Gendron D, Evans AC, Gjeddi A, et al. 1990. Neurologic sequelae of domoic acid intoxication due to the ingestion of contaminated mussels. N Engl J Med 332:1781-1787.
58. Thiruchelvam M, McCormack J, Richfield EK, Baggs RB, Tank AW, Di Monte DA, et al. 2003. Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. Eur J Neurosci 18:589-600.
59. Thiruchelvam M, Richfield EK, Goodman BM, Baggs RB, Core-Slechta DA. 2002. Developmental exposure to the pesticides paraquat and maneb and the Parkinson's disease phenotype. Neurotoxicology 23:621-633.
60. Tranchand B, Laporte S, Glehen O, Freyer G. 2003. Pharmacology of cytotoxic agents: a helpful tool for building dose adjustment guidelines in the elderly. Crit Rev Oncol Hematol 48:199-214.
61. Van Dam J, Zeldis JB. 1990. Hepatic diseases in the elderly. Gastroenterol Clin North Am 19:459-472.
62. Van Den Brande P, Van Steenbergen W, Vervoort G, Demedts M. 1995. Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis. Am J Respir Crit Care Med 152:1705-1708.
63. Vogel S, Contois JH, Tucker KL, Wilson PW, Schaefer EJ, Lammi-Keefe CJ. 1997. Plasma retinol and plasma and lipoprotein tocopherol and carotenoid concentrations in healthy elderly participants of the Framingham Heart Study. Am J Clin Nutr 66:50-958.
64. Ward JM, Lynch P, Riggs C. 1988. Rapid development of hepatocellular neoplasms in aging male C3H/HeNCr mice given phenobarbital. Cancer Lett 39:9-18.
65. Weiss B. 2000. Vulnerability to pesticide neurotoxicity is a life-time issue. Neurotoxicology 21:67-74.
66. Wouters-Wesseling W, Wagenaar LW, de Groot LC, Bindels JG, van Staveren WA. 2003. Biochemical antioxidant levels respond to supplementation with an enriched drink in frail elderly people. J Am Coll Nutr 22:232-238.
67. Wozniak DF, Stewart GR, Miller JP, Olney JW. 1991. Age-related sensitivity to kainite neurotoxicity. Exp Neurol 114:250-253.
68. Zarling EJ, Mobarhan S, Bowan P, Kamath S. 1993. Pulmonary pentane excretion increases with age in healthy subjects. Mech Aging Dev 67:141-147.
69. Zeeh J, Platt D. The aging liver: structural and functional changes and their consequences for drug treatment in old age [published erratum Gerontology 48(4):265. Gerontology 48(3):121-127.